BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32753543)

  • 1. Is there a link between very early changes of primary and secondary lymphoid organs in
    Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing immune organs on
    Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
    J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the role of colonic and other anatomical sites uptake by [
    Rizzo A; Cantale O; Mogavero A; Garetto L; Racca M; Venesio T; Anpalakhan S; Novello S; Gregorc V; Banna GL
    Thorac Cancer; 2023 Aug; 14(24):2473-2483. PubMed ID: 37442801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of integrated
    Umeda Y; Morikawa M; Anzai M; Ameshima S; Kadowaki M; Waseda Y; Shigemi H; Tsujikawa T; Kiyono Y; Okazawa H; Ishizuka T
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
    Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Dyall J; Johnson RF; Chefer S; Leyson C; Thomasson D; Seidel J; Ragland DR; Byrum R; Jett C; Cann JA; St Claire M; Jagoda E; Reba RC; Hammoud D; Blaney JE; Jahrling PB
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28814515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of
    Wang G; Zhang W; Luan X; Wang Z; Liu J; Xu X; Zhang J; Xu B; Lu S; Wang R; Ma G
    Front Immunol; 2023; 14():1151967. PubMed ID: 37215117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of
    Kaira K; Kuji I; Kagamu H
    Cancer Imaging; 2021 Jan; 21(1):11. PubMed ID: 33441183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
    Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
    J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with
    Paternain A; García-Velloso MJ; Rosales JJ; Ezponda A; Soriano I; Elorz M; Rodríguez-Otero P; Aquerreta JD
    Eur J Radiol; 2020 Dec; 133():109403. PubMed ID: 33202373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bone marrow and spleen
    Lee JH; Lee HS; Kim S; Park EJ; Baik SH; Jeon TJ; Lee KY; Ryu YH; Kang J
    Sci Rep; 2021 Jun; 11(1):12137. PubMed ID: 34108552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
    Goense L; Heethuis SE; van Rossum PSN; Voncken FEM; Lagendijk JJW; Lam MGEH; Terhaard CH; van Hillegersberg R; Ruurda JP; Mook S; van Lier ALHMW; Lin SH; Meijer GJ
    Nucl Med Commun; 2018 Jan; 39(1):60-67. PubMed ID: 29023336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can benign lymphoid tissue changes in
    Sachpekidis C; Larribère L; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2019 Feb; 68(2):297-303. PubMed ID: 30478475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.